Byron Bay Bio, an Australian biotech company, has made a groundbreaking advancement in DNA genome sequencing. This innovation allows for the precise standardization of cannabis potency and its effects, paving the way for truth in labeling — a critical step toward legalization. This new technology also enables the identification and patenting of unique cannabis strains, providing the consistency and safety that regulators need. “Alcohol bottles have labels stating the percentage of alcohol content — cannabis needs reliable labeling of THC and CBD to ensure safety for everyone, and this is what our technology enables,” said Jeff Lang, CEO of Byron Bay Bio. “The importance of this advancement cannot be overstated. Imagine selling a bottle of vodka without knowing whether it contains 38% or 65% alcohol — no government would permit such a sale.” This DNA genome sequencing, which standardizes cannabis strength and its effect on the human body, is considered one of the main hurdles preventing legalization across the globe. By stabilizing strains, improving breeding practices, and ensuring crop health, this genetic testing of cannabis can lead to more consistent and reliable cannabis products.